The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
ALS patients experience neuroinflammation and rapid neurodegeneration
Also received tentative approval for 137 mg
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Subscribe To Our Newsletter & Stay Updated
